ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin

Oncogene

Volumn 34, Issue 12, 2015, Pages 1553-1562

  Feduska, J M ^a   Aller, S G ^a   Garcia, P L ^a   Cramer, S L ^b   Council, L N ^c   Van Waardenburg, R C A M ^a   Yoon, K J ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CELL ADHESION MOLECULE; ICAM-2 PROTEIN, MOUSE; ICAM2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROTEIN BINDING;

ANIMAL; BINDING SITE; CELL ADHESION; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; MUTATION; NEUROBLASTOMA; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ACTINS; ANIMALS; ANTIGENS, CD; BINDING SITES; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, SCID; MODELS, MOLECULAR; MUTATION; NEOPLASM METASTASIS; NEUROBLASTOMA; PROTEIN BINDING;

EID: 84897355474     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.87     Document Type: Article

References (46)

1. Casasnovas JM, Springer TA, Liu JH, Harrison SC, Wang JH. Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Nature 1997;387: 312-315.
2. Nortamo P, Li R, Renkonen R, Timonen T, Prieto J, Patarroyo M et al. The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol 1991;21: 2629-2632.
3. de Fougerolles AR, Stacker SA, Schwarting R, Springer TA. Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med 1991;174: 253-267.
4. Kotovuori A, Pessa-Morikawa T, Kotovuori P, Nortamo P, Gahmberg CG. ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity. J Immunol 1999;162: 6613-6620.
5. Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS One 2008;3: e3629.
6. Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989;339: 61-64.
7. Huang MT, Mason JC, Birdsey GM, Amsellem V, Gerwin N, Haskard DO et al. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 2005;106: 1636-1643.
8. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 1994;94: 1243-1251.
9. Hamada K, Shimizu T, Yonemura S, Tsukita S, Hakoshima T. Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J 2003;22: 502-514.
10. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S et al. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 1998;140: 885-895.
11. Heiska L, Alfthan K, Gronholm M, Vilja P, Vaheri A, Carpen O. Association of ezrin with intercellular adhesion molecule-1 and-2 (ICAM-1 and ICAM-2). Regulation by phosphatidylinositol 4, 5-bisphosphate. J Biol Chem 1998;273: 21893-21900.
12. Heiska L, Kantor C, Parr T, Critchley DR, Vilja P, Gahmberg CG et al. Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to alpha-actinin. J Biol Chem 1996;271: 26214-26219.
13. Geijtenbeek TB, Krooshoop DJ, Bleijs DA, van Vliet SJ, van Duijnhoven GC, Grabovsky V et al. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 2000;1: 353-357.
14. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H et al. Actinin-4, a novel actinbundling protein associated with cell motility and cancer invasion. J Cell Biol 1998;140: 1383-1393.
15. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005;128: 51-62.
16. Sun CX, Robb VA, Gutmann DH. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Science 2002;115: 3991-4000.
17. Otey CA, Carpen O. Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton 2004;58: 104-111.
18. Liu J, Taylor DW, Taylor KA. A 3-D reconstruction of smooth muscle alpha-actinin by CryoEm reveals two different conformations at the actin-binding region. J Mol Biol 2004;338: 115-125.
19. Atkinson RA, Joseph C, Kelly G, Muskett FW, Frenkiel TA, Nietlispach D et al. Ca2 +independent binding of an EF-hand domain to a novel motif in the alphaactinin-titin complex. Nat Struct Biol 2001;8: 853-857.
20. DeLisser HM, Chilkotowsky J, Yan HC, Daise ML, Buck CA, Albelda SM. Deletions in the cytoplasmic domain of platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) result in changes in ligand binding properties. J Cell Biol 1994;124: 195-203.
21. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279: 19008-19017.
22. Pasqualini R, Hemler ME. Contrasting roles for integrin beta 1 and beta 5 cytoplasmic domains in subcellular localization, cell proliferation, and cell migration. J Cell Biol 1994;125: 447-460.
23. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3: 362-374.
24. Eccles SA, Box C, Court W. Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol Ann Rev 2005;11: 391-421.
25. Feduska JM, Garcia PL, Brennan SB, Bu S, Council LN, Yoon KJ. N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells. BMC Cancer 2013;13: 261.
26. Cifone MA, Fidler IJ. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 1980;77: 1039-1043.
27. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G et al. Anchorageindependent cell growth signature identifies tumors with metastatic potential. Oncogene 2009;28: 2796-2805.
28. Melero I, Gabari I, Corbi AL, Relloso M, Mazzolini G, Schmitz V et al. An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. Cancer Res 2002;62: 3167-3174.
29. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011;140: 310-321.
30. Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cellbased immunotherapies for pancreatic cancer. J Gastroenterol Hepatol 2009;24: 900-911.
31. Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, Nolan GP et al. Activation of the PKB/AKT pathway by ICAM-2. Immunity 2002;16: 51-65.
32. Hogg N, Stewart MP, Scarth SL, Newton R, Shaw JM, Law SK et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest 1999;103: 97-106.
33. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69: 11-25.
34. Yang Y, Jun CD, Liu JH, Zhang R, Joachimiak A, Springer TA et al. Structural basis for dimerization of ICAM-1 on the cell surface. Molecular cell 2004;14: 269-276.
35. Hariharan R, Pillai MR. Structure-function relationship of inhibitory Smads: Structural flexibility contributes to functional divergence. Proteins 2008;71: 1853-1862.
36. Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 2003;50: 437-450.
37. Eisenberg D, Luthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Meth Enzymol 1997;277: 396-404.
38. Tovchigrechko A, Vakser IA. Development and testing of an automated approach to protein docking. Proteins 2005;60: 296-301.
39. Mohamet L, Lea ML, Ward CM. Abrogation of E-cadherin-mediated cellular aggregation allows proliferation of pluripotent mouse embryonic stem cells in shake flask bioreactors. PLoS One 2010;5: e12921.
40. Nyman-Huttunen H, Tian L, Ning L, Gahmberg CG. alpha-Actinin-dependent cytoskeletal anchorage is important for ICAM-5-mediated neuritic outgrowth. J Cell Sci 2006;119: 3057-3066.
41. Morton CL, Iacono L, Hyatt JL, Taylor KR, Cheshire PJ, Houghton PJ et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56: 629-636.
42. Garcia PL, Council LN, Christein JD, Arnoletti JP, Heslin MJ et al. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One 2013;8: e78183.
43. Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.3r1 2010.
44. Humphries MJ. Cell-substrate adhesion assays. Current Protocols in Cell Biology 2001, 00: 9119111.
45. Carpen O, Pallai P, Staunton DE, Springer TA. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin. J Cell Biol 1992;118: 1223-1234.
46. Otey CA, Vasquez GB, Burridge K, Erickson BW. Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J Biol Chem 1993;268: 21193-21197.